TLDR:
- Endoron Medical, a medtech company in Israel, raised $10M in Series A funding led by Sofinnova Partners and the European Innovation Council Fund.
- The funding will be used to accelerate the clinical validation of its flagship product, the catheter-based EndoStapling solution Aortoseal.
Endoron Medical, a Tel Aviv-based medtech company specializing in endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms, recently announced that it has secured $10M in Series A funding. The round was led by Sofinnova Partners, with participation from the European Innovation Council Fund (EIC Fund). The company, founded by Ronit Harpaz, Prof. Ron Karmeli, and Eyal Teichman, focuses on developing technologies for the endovascular repair of abdominal aortic aneurysms (AAA).
Endoron’s flagship product, the catheter-based EndoStapling solution Aortoseal, aims to address the challenges of sealing and securing endografts used in minimally invasive AAA repairs, especially in complex procedures. The stapling mechanism provided by Endoron ensures complete sealing of endografts while securely anchoring them, thus preventing long-term migration and endoleaks. This not only reduces the need for highly invasive, high-mortality open surgeries but also improves patient outcomes.
The funding from this Series A round will be utilized by Endoron Medical to accelerate the clinical validation of its flagship product, Aortoseal, as it progresses through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS). With the support from Sofinnova Partners and the EIC Fund, Endoron aims to advance the development and commercialization of its innovative endograft stapling solutions, ultimately improving the standard of care for patients undergoing endovascular repair of abdominal aortic aneurysms.
